Key result
Acute administration of pyridostigmine 30 mg significantly lowered standing heart rate at 2 hours compared to placebo (100 vs 111 bpm, P=0.001) and improved symptom burden in POTS patients.
Why the study?
Does pyridostigmine reduce tachycardia and improve symptom burden in patients with postural tachycardia syndrome?
Population
17 patients with Postural tachycardia syndrome (POTS)
Comparison
Pyridostigmine 30 mg orally vs Placebo
Design
RCT, randomized crossover design
Follow-up
4 hours
Authors
Loading...
Supports acute pyridostigmine evaluation in POTS; extends randomized evidence for acetylcholinesterase inhibition in orthostatic intolerance.
RCT (n=17)
Crossover
Does pyridostigmine reduce tachycardia and improve symptom burden in patients with postural tachycardia syndrome?
Absolute Event Rate: 100% vs 111%
p-value: p=0.001
Acute acetylcholinesterase inhibition with pyridostigmine significantly attenuates tachycardia and improves symptoms in patients with POTS.
Raj et al. (2005) conducted an RCT in Postural tachycardia syndrome (POTS) (n=17). pyridostigmine vs. placebo was evaluated on Heart rate at 2 hours after study drug (p=0.001). Acute administration of pyridostigmine 30 mg significantly lowered standing heart rate at 2 hours compared to placebo (100 vs 111 bpm, P=0.001) and improved symptom burden in POTS patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: